trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Triple-negative breast cancer and HER2-positive breast cancer are more immunogenic than luminal-like breast cancer.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Triple-negative breast cancer and HER2-positive breast cancer are more immunogenic than luminal-like breast cancer?

Yes. Multiple studies consistently demonstrate that triple-negative and HER2-positive breast cancers feature significantly higher tumor-infiltrating lymphocytes and immunogenicity than luminal-like breast cancers.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The retrieved literature consistently supports the assertion that triple-negative and HER2-positive breast cancer subtypes have higher immunogenic features, such as increased tumor-infiltrating lymphocytes and better responses to immunotherapies or neoadjuvant regimens, compared to luminal-like breast cancers. There are no papers contradicting this established oncological consensus.

Evidence for · 3
Predictors of Pathological Complete Response and Patient-Reported Outcomes During Neoadjuvant Chemotherapy in Early Breast Cancer: A Single-Center Retrospective Cohort Study.
2026
Get citation
IA, K., AS, G., EA, I., LA, K., B, G., & D, S. (2026). Predictors of Pathological Complete Response and Patient-Reported Outcomes During Neoadjuvant Chemotherapy in Early Breast Cancer: A Single-Center Retrospective Cohort Study.. doi.org. https://doi.org/10.7759/cureus.109160

See more details
More for · 2
Dynamic Changes in PD-L1, VEGF, and TILs Following Neoadjuvant Therapy in Residual Invasive Breast Cancer.
2026
Get citation
M, B., J, R., A, K. P., & S, K. (2026). Dynamic Changes in PD-L1, VEGF, and TILs Following Neoadjuvant Therapy in Residual Invasive Breast Cancer.. doi.org. https://doi.org/10.3390/cimb48090899

Tumor-Infiltrating Lymphocytes as Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: Added Value of Morphological Characterization Beyond Quantification.
2026
Get citation
J, A., A, P., T, S., E, Q., A, V., A, S., A, G., MJ, P., H, P., A, G., R, O., D, P., C, C., M, V., LM, M., MDR, T., E, G., J, B., A, V., E, M., S, P., M, G., & C, F. (2026). Tumor-Infiltrating Lymphocytes as Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: Added Value of Morphological Characterization Beyond Quantification.. doi.org. https://doi.org/10.3390/cancers18132065

What does the evidence say?

The retrieved literature consistently supports the assertion that triple-negative and HER2-positive breast cancer subtypes have higher immunogenic features, such as increased tumor-infiltrating lymphocytes and better responses to immunotherapies or neoadjuvant regimens, compared to luminal-like breast cancers. There are no papers contradicting this established oncological consensus.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work